Anagrelid ile İlişkili Bacak Ülserleri

Kaynakça (9)

1. Cozzani E, Iurlo A, Merlo G, Cattaneo D, Burlando M, Pierri I, Gugliotta L, Parodi A. Essential thrombocythemia: the dermatologic point of view. Clin Lymhoma Myeloma Leuk 2015;15:739-747
2. Birgegård G. Long-term management of thrombocytosis in essential thrombocythaemia. Ann Hematol 2009;88:1-10
3. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006;66:111-131
4. Dingli D, Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 2005;46:641-650
5. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720- 1728
6. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Ruiz- Reyes G, Chernoff SG. Anagrelide induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia. Mayo Clin Proc 1998;73:1125
7. Rappoport L, Körber A, Grabbe S, Dissemond J. Appearance of leg ulcers associated with intake of anagrelide. Dtsch Med Wochenschr 2007;132:319- 321
8. Simeonovski V, Breshkovska H, Duma S, Dohcheva-Karajovanov I, Damevska K, Nikolovska S. hydroxyurea associated cutaneous lesions: a case report. Open Access Maced J Med Sci 2018;6:1458-1461
9. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 2005;16:181- 184.